Global Diabetes Diagnostics Size 2025, Forecast To 2034
26 Mar, 2025
What Fueled The Previous Growth In The Diabetes Diagnostics Market?
The diabetes diagnostics market has seen considerable growth due to a variety of factors.
• The market size for diabetes diagnostics has seen a significant increase in the past few years. The market is projected to expand from $25.39 billion in 2024 to $27.39 billion in 2025, representing a compound annual growth rate (CAGR) of 7.9%.
The historical growth in this market is associated with a surge in diabetes cases, growth in the ageing population, the rise in sedentary lifestyles, a trend towards minimally invasive diagnostics, and an increase in obesity rates.
How Does the Forecast Look for the Diabetes Diagnostics Market?
The diabetes diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the diabetes diagnostics market is projected to experience robust growth, reaching $36.72 billion by 2029 with a compound annual growth rate (CAGR) of 7.6%.
The spike in growth during the projected period is due to the growing use of insulin pumps, advancements in diabetes technology, an increase in unhealthy lifestyle habits, a rise in type 1 and type 2 diabetes prevalence, and an expanded healthcare infrastructure. Key trends for the projected period include improvements in biosensor technology, technological advancements, progress in diagnostic technologies, personalized medicine and targeted therapies, and sophisticated in vitro diagnostic technologies.
What Are The Leading Drivers Of Growth In The Diabetes Diagnostics Market?
The augmenting instances of obesity are anticipated to foster the expansion of the diabetes diagnostics market in the future. Obesity, defined as the excessive accumulation of body fat, raises the likelihood of numerous health issues, including heart disease and diabetes. The escalating prevalence of obesity may be linked to factors like sedentary lifestyles, amplified intake of processed and high-calorie foods, genetic factors, and inadequate physical activity. Diabetes diagnostics facilitate the management of obesity by early detection of insulin resistance and glucose metabolism disorders, permitting prompt intervention to avert weight gain and associated health problems. For instance, as per September 2023 data from the Centers for Disease Control and Prevention, a government agency from the US, there were 22 states in 2022 with an adult obesity rate of 35% or more, a rise from 19 states in 2021. Consequently, the escalating prevalence of obesity is steering the expansion of the diabetes diagnostics market.
How Are The Segments Defined Within The Global Diabetes Diagnostics Market?
The diabetes diagnostics market covered in this report is segmented –
1) By Product Type: Blood Glucose Meters, Continuous Glucose Monitoring Devices, Lancets, Test Strips, Other Product Types
2) By Diabetes Type: Diabetes I, Diabetes II, Gestational Diabetes
3) By End-User: Hospitals, Diagnostic Centers, Homecare Settings, Other End-Users
Subsegments:
1) By Blood Glucose Meters: Traditional Blood Glucose Meters, Smart Blood Glucose Meters, Bluetooth-enabled Blood Glucose Meters
2) By Continuous Glucose Monitoring Devices: Wearable CGM Systems, Implantable CGM Systems, Flash Glucose Monitoring Devices
3) By Lancets: Single-use Lancets, Multi-use Lancets
4) By Test Strips: Standard Test Strips, Smart Test Strips
5) By Other Product Types: Hemoglobin A1c Testing Kits, Urine Glucose Test Strips, Blood Ketone Meters
How Are New Trends Expected To Influence The Growth Of The Diabetes Diagnostics Market?
Major players in the diabetes diagnostics market are focusing their efforts on creating pioneering items like gestational diabetes diagnostic apparatus, seeking to broaden their range of products and satisfy the increasing need for early diagnosis and management of diabetes during pregnancy. Medical devices or tests used to track and identify gestational diabetes in expectant women, which typically involves blood glucose testing such as the oral glucose tolerance test (OGTT), are known as gestational diabetes diagnostic tools. For example, DirectSens GmbH, a bio-technology firm based in Austria, introduced the XpressGT RUO kit in August 2024. This innovative biosensor tool is specifically designed to identify conditions tied to insulin resistance such as gestational diabetes, endometriosis, and liver disease. The kit can quickly measure 2-hydroxybutyrate (2-HB) levels in venous blood and is adaptable with regular clinical analyzers. The purpose of this innovation is to provide early diagnostics that could potentially enhance outcomes for millions of patients around the globe.
Who Are the Key Players In The Diabetes Diagnostics Market?
Major companies operating in the diabetes diagnostics market are:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Bayer AG
• Abbott Laboratories
• Novartis AG
• 3M Company
• Medtronic plc
• Regeneron Pharmaceuticals Inc.
• Carl Zeiss Meditec AG
• Bausch & Lomb Incorporated
• DexCom Inc
• Santen Pharmaceutical Co. Ltd.
• Topcon Corporation
• Tandem Diabetes Care Inc
• Ypsomed AG
• LifeScan Inc
• Nova Biomedical Corporation
• Ascensia Diabetes Care Holdings AG
• ARKRAY Inc
• Optos plc
• Bioland Technology Ltd
• PTS Diagnostics Inc
• AgaMatrix Inc
• Senseonics Holdings Inc
• DarioHealth Corp.
What Is The Most Dominant Region In The Diabetes Diagnostics Market?
North America was the largest region in the diabetes diagnostics market in 2024. The regions covered in the diabetes diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.